Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.5.0.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Revenues $ 135 $ 160
Operating expenses:    
Research and development (related parties of $239 and $227), net of $36 and $0 in grant income 820 551
General and administrative (related parties of $175 and $0) 2,469 1,422
Total operating expenses 3,289 1,973
Operating loss (3,154) (1,813)
Other income (expense):    
Interest expense (related party of $483 and $0) (483) 0
Interest income 13 2
Royalty income 12 6
Total other income (458) 8
Consolidated net loss (3,612) (1,805)
Net loss attributable to noncontrolling interest 551 0
Net loss attributable to iBio, Inc. (3,061) (1,805)
Comprehensive loss:    
Net loss (3,612) (1,805)
Other comprehensive loss - foreign currency translation adjustments 0 (9)
Comprehensive loss $ (3,612) $ (1,814)
Loss per common share - basic and diluted $ (0.03) $ (0.02)
Weighted-average common shares outstanding - basic and diluted 89,109 77,307